A recent study shows evidence for a biomarker of efficacious treatment that may be used to assess other glutamatergic or GABAergic medications for alcohol use disorder (AUD) and related conditions, as well as provide insight into the means through which gabapentin may promote abstinence in individuals with AUD.
Varenicline alone is an adequate therapy for smoking cessation in heavy-drinking smokers, but combining it with naltrexone may provide benefits in terms of drinking outcomes, particularly during the 12-week period of active medication treatment, suggests a study.
Clinical insomnia was reported in one-third of Hong Kong citizens during the third wave of the coronavirus disease 2019 (COVID-19) outbreak, with over 60 percent having persistent insomnia in both the second and third waves, according to a recent longitudinal follow-up study in Hong Kong.
In individuals with dementia-related psychosis (DRP) who had a response to the oral 5-HT2A* inverse agonist and antagonist pimavanserin, an atypical antipsychotic agent, the risk of relapse was lower among those who continued the drug vs those who stopped it, the phase III HARMONY trial suggests.
Heart rate variability (HRV) may be a valuable, noninvasive, easily accessible marker to monitor worsening suicidality among adolescents, according to a recent study. Wearable devices such as fitness trackers could facilitate such monitoring, allowing for timely detection and intervention.
Elevated counts of circulating endothelial progenitor cells (cEPCs) are correlated to worse anxiety, more severe depressive symptoms, poorer cognitive performance, greater social disability, and impaired overall mental health in patients with major depressive disorder (MDD), a recent study has found.